Liver-type glutaminase (LGA) as a modulator of the WNT signaling pathway.


Project proposed under the KNOW PhD studies in MMRC

“Liver-type glutaminase (LGA) as a modulator of the WNT signaling pathway.”

Supervisor: Jan Albrecht, PhD, Prof. / Monika Szeliga, PhD

Neurotoxicology Department,

contact: Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie w przeglądarce obsługi JavaScript., Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie w przeglądarce obsługi JavaScript.; 22 60 86 416

 

Phosphate-activated glutaminase (PAG), which  metabolizes glutamine (Gln) to glutamate (Glu) and ammonia occurs in mammals in two isoforms:  kidney-type (KGA) and liver-type (LGA). LGA is hardly detectable in highly malignant glial tumors. Consistent with the hypothesis implicating LGA in the regulation of transcription, our previous study revealed that transfection of a full cDNA sequence encoding human LGA to glioblastoma T98G cell line decreased cell proliferation and migration ability and  significantly altered the expression level of 85 genes (M. Szeliga et al., Glia, 2009). At least three of the down-regulated genes: RYK, FHL2 and Capn2 code for proteins related to the Wnt signaling pathway, aberrations of which play a role in the proliferation and migration of glioma cells. The aim of the proposed project is to investigate the hypothesis that LGA acts as a modulator of the Wnt signaling pathway. Selected elements of the Wnt pathway will be compared in wild and LGA-transfected T98G cells.

 

The candidate should first contact the Supervisor to complete the application procedure.